ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company which engaged in improving patients' lives by overcoming resistance in cancer. Co. develops therapies targeting hormone-dependent cancers, precision oncology, and key tumor dependencies. Co.'s clinical-stage products include ORIC-114, a brain-penetrant inhibitor targeting EGFR and HER2 for genetically defined cancers; ORIC-944, an allosteric inhibitor of PRC2 for prostate cancer; and ORIC-533, an orally bioavailable inhibitor of CD73, which plays a role in resistance to chemotherapy and immunotherapy. The ORIC average annual return since 2020 is shown above.
The Average Annual Return on the ORIC average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ORIC average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ORIC average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|